Work

Targeting LL-37-Driven Psoriasiform Inflammation with Apolipoprotein A-I

Year: 2026
Type: preprint
Abstract: Psoriasis is a chronic inflammatory skin disease characterized by dysregulated innate and adaptive immune responses. The antimicrobial peptide LL-37 is increased in psoriatic skin and can promote inflammation through effects on cellular damage, leukocyte recruitment, cytokine production, and the formation of immunostimulatory complexes with self-derived nucleic acids. Here, we investigated whether the human plasma protein apolipoprotein A-I (ApoA-I) can regulate LL-37 activity and thereby attenuate psoriasis-associated inflammation. We show that ApoA-I acts as a scavenger of LL-37 and that its administration confers therapeutic benefits in psoriatic skin, as demonstrated in an experimental animal model and human ex vivo models. Mechanistically, ApoA-I limited nucleic acid uptake and TLR-dependent type I interferon responses in plasmacytoid dendritic cells and keratinocytes. In an experimental mouse model, ApoA-I attenuated imiquimod-induced psoriasiform inflammation, reducing clinical, histological, and molecular disease features, while also suppressing inflammatory mediators and psoriasis-associated biomarkers in a human 3D psoriatic skin model. Together, these findings identify ApoA-I as a previously unrecognized regulator of LL-37-driven skin inflammation and suggest that therapeutic strategies aimed at restoring or mimicking ApoA1´s LL-37-scavenging mechanisms may have potential for treatment of psoriasis and related inflammatory skin diseases.
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W7236682253
Cites: 77
Cited by:
Related to: 10